CRISPR Therapeutics AG - Common Shares (CRSP)

These companies are leaders in their fields.

The biotech's candidate may treat a great number of illnesses that have one thing in common.

This particular player has seen its yield rise in recent years.

These stocks come with risk, but they also have some exciting long-term growth opportunities.

We'll know more about the company's medium-term prospects by the end of the year.

The company's strong cash position gives investors confidence in the gene-editing stock.

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.

The gene-editing stock has been in a tailspin of late.

As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant dominated the CF landscape with its groundbreaking CFTR modulators, but today, the narrative has shifted to a broader multi-disease platform. With the successful 2025 launch of [...]

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies.

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.

The firm believes the new lineup could significantly expand Rivian's addressable EV market.

These two biotechs have a lot in common. Their differences are even more pronounced.

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Could these three stocks be Cathie Wood's next big winners?

The past few years have been challenging for the biotech.

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

These biotech companies have catalysts ahead.

The company could finally be ready to deliver on years of promise.

2026 could be a big year for this company.